Skip to content
Open access

Empagliflozin and Metformin Combination Therapy Attenuates Oxidative Stress and Inflammation in Experimental Cardio–Kidney–Metabolic Syndrome

Oct 2026 · International Journal of Molecular Sciences · Vol 27, pp. 8988 · 0 citations · 98 references
Medicine

TL;DR

Overall, the E+M combination attenuated metabolic alterations and suppressed renal oxidative stress and inflammation, providing cardiac and renal protection at both functional and structural levels.

Abstract

This study evaluated the therapeutic effects of the empagliflozin+metformin (E+M) combination on cardio–kidney–metabolic syndrome (CKMS) using an experimental model. Animals were fed a Paigen-type (high-fat) diet supplemented with sugar-sweetened beverages to induce the CKMS phenotype. After confirming metabolic, cardiovascular, and renal alterations, animals were randomized into untreated and E+M-treated groups for 30 days while continuing the diet. Cardiovascular risk factors, vasoactive substances in the heart and kidney, oxidative stress, and the expression of inflammatory markers and the lipogenic transcription factors ChREBP and SREBP1 were analyzed. The E+M combination reduced body weight, hyperglycemia, fasting glucose, and hypertension, while restoring the lipid profile and improving oral glucose tolerance and renal function (p < 0.05). It also reduced posterior wall and interventricular septal thickening, as well as the elevated septum/posterior wall (PP/PS) ratio observed in the CKMS group (p < 0.05). Likewise, the increases in angiotensin II and nitric oxide concentrations in the hearts and kidneys were attenuated (p < 0.05). The CKMS group exhibited glomerular hypertrophy and reduced total antioxidant capacity mitochondrial complex I and II activities, glutathione peroxidase, glutathione reductase, and superoxide dismutase activities, and Nrf2 and IL-10 expression, all of which were restored by combination therapy (p < 0.05). In contrast, the upregulation of IGF-1, aldose reductase, sorbitol dehydrogenase, ChREBP, IL-6, TNFα, and NF-κB observed in the CKMS group was reduced following E+M treatment (p < 0.05). Overall, the E+M combination attenuated metabolic alterations and suppressed renal oxidative stress and inflammation, providing cardiac and renal protection at both functional and structural levels. These effects appear to be mediated by the modulation of key proteins involved in vascular tone, uric acid metabolism, oxidative stress, inflammation, and regulation of transcription factors involved in carbohydrate and lipid metabolism.

Read PDF

Similar papers

Open access Sep 2026

Effects of Liraglutide and Semaglutide on Cardiometabolic Dysregulation and Oxidative Stress in an Experimental Model of Metabolic Syndrome

Liraglutide and semaglutide exerted significant cardioprotective and tissue-protective effects in experimental MetS complicated by myocardial I/R injury, and their potential in limiting post-ischemic cardiac dysfunction and multiorgan damage in metabolically compromised conditions is supported.

M. Ravić, I. Srejović, M. Andjic et al. · 0 citations
Open access 2026

Dapagliflozin and metformin combination therapy modulates lipid metabolism and oxidative stress in a sex-dependent manner

Purpose: To investigate the effect of dapagliflozin combined with metformin on metabolic, oxidative and endothelial factors, with a particular focus on sex-specific variation.Methods: A total of 32 patients (18 males, 14 females) were recruited from Al-Salam Teaching Hospital in Mosul city, Iraq. The patients received...

Hani M. Almukhtar, Adil M. Najm, S. H. Othman · 0 citations
Open access Oct 2026

D-allulose attenuates dyslipidemia, oxidative stress, and inflammation in high-fat-diet-induced metabolic dysfunction-associated steatotic liver disease in rats

D-allulose shows promising protective impacts as a bioactive ingredient for obesity-related metabolic disorders and attenuated HFD-induced hepatic steatosis, degeneration, necrosis, inflammation, and early fibrosis, while improving antioxidant status.

Sami O. Almutairi, A. E. A. Yagoub, H. Barakat · 0 citations
Sep 2026

Co-administration of empagliflozin and curcumin attenuates the development of MASLD by modulating lipid metabolism and adipose tissue browning in HFD-fed C57BL/6J mice.

The increasing global incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) highlights the need for effective treatment strategies. This study investigated the combined effects of empagliflozin (EMPA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and curcumin (Cur), a natural polyphenol,...

Masoume Aliabadi, A. Soleimani, G. Taheripak et al. · 0 citations
Open access Oct 2026

Sotagliflozin Reprograms Hepatic Lipid Metabolism and Attenuates Atherosclerosis Beyond Empagliflozin in CKM Mice

Background Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce cardiovascular mortality and chronic kidney disease (CKD) progression in cardiovascular-kidney-metabolic (CKM) syndrome, but this benefit derives primarily from reductions in heart failure and cardiovascular mortality rather than in atherothrombotic ev...

Keith L. Saum, Jessica Sim, L. Zeng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.